Drug Profile
IO 101
Alternative Names: IO101Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Herlev Hospital; IO Biotech
- Class Antineoplastics; Cancer vaccines; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in Denmark (SC)
- 13 Apr 2018 Efficacy data from a phase I trial in Non-small cell lung cancer released by IO Biotech before April 2018 (IO Biotech pipeline, April 2018)